Market Place
Sourcing Support
MicuRx to Present 15 Studies at ESCMID Global 2025
08 Apr 2025 //
PR NEWSWIRE
MicuRx Contezolid Ph 3 Trial Passes Safety Review For DFI Treatment
25 Feb 2025 //
PR NEWSWIRE
FDA Grants Orphan Drug Designation to MicuRx for NTM Infections
02 Jan 2025 //
PR NEWSWIRE
MicuRx Successfully Completes Ph 3 Trial Of MRX-4 For Injection
29 Nov 2024 //
PR NEWSWIRE
MicuRx Completes Phase 1 Trial of MRX-5 in Australia
25 Oct 2024 //
PR NEWSWIRE
MicuRx Showcases MRX-5 And MRX-8 At BIO Investor Forum
18 Oct 2024 //
PR NEWSWIRE
MicuRx Announces Results From MRX-5 Study For Infections
07 Oct 2024 //
PR NEWSWIRE
MicuRx Presents Antibiotic Research At World Bronchiectasis Conference
18 Jul 2024 //
PR NEWSWIRE
MicuRx To Present Data At 7th World Bronchiectasis Conference
19 Jun 2024 //
PR NEWSWIRE
MicuRx Completes Phase 1 Trial Of MRX-8 Antibacterial In China
06 Jun 2024 //
PR NEWSWIRE
MicuRx announces poster presentation & participation in ID Week 2023 Conference
11 Oct 2023 //
PR NEWSWIRE
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx
08 Feb 2023 //
PR NEWSWIRE
China NMPA Approves MicuRx`s Contezolid for Treatment of Drug-Resistant
03 Jun 2021 //
PRNASIA
MicuRx Announces CARB-X US$7.78 Million Funding for Development of MRX-8
12 Aug 2020 //
PRNEWSWIRE
MicuRx Positive Results of Ph 3 Trial for Contezolid in Skin & Soft Tissue Inf.
19 Sep 2019 //
BIOSPACE
MicuRx Announces Receipt of FDA’s Fast Track Designations for Contezolid
21 Sep 2018 //
BUSINESSWIRE
Hong Kong exchange picks up steam with two biotech IPOs from Innovent, MicuRx
04 Jul 2018 //
ENDPTS
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.